Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 1/2011

01-02-2011 | Original Article

Is glucosamine-chondroitin risky to normoglycemic individuals with family history of diabetes mellitus

Authors: Rafi A. M. Al-Razzuqi, Ali A. Al-Jeboori

Published in: International Journal of Diabetes in Developing Countries | Issue 1/2011

Login to get access

Abstract

Many studies have examined the therapeutic effects of glucosamine and chondroitin in relieving joint pains, but they did not determine any abnormal pharmacodynamic interactions. To determine the relationship between glucosamine-chondroitin supplement and occurrence of hyperglycemia in normoglycemic patients with family history of diabetes mellitus. 84.9% normoglycemic patients with family history of diabetes became hyperglycemic after 8 weeks course of glucosamine-chondroitin supplement ingestion. Patients who had diabetic female relatives were at risk and they represented 92.3%. When hypoglycemic agents were used, hyperglycemic patients with diabetic male relatives rapidly became normoglycemic at the end of 2nd post treatment week and they represented 83.3% of hyperglycemic patients. Only 2.5% resisted treatment. Glucosamine-chondroitin supplement, although has few side effects, it should be used with great caution in normoglycemic patients with family history of diabetes mellitus and especially those who had diabetic female relatives.
Literature
1.
go back to reference Conn D, Rutherfeild WG, Gallopers A. Alternative treatments and rheumatic diseases. Bulletin on Rheum Dis. 1999;48:1–4. Conn D, Rutherfeild WG, Gallopers A. Alternative treatments and rheumatic diseases. Bulletin on Rheum Dis. 1999;48:1–4.
2.
go back to reference DeCamara J, Dowless H. Glucosamine sulfate role in osteoarthritis. Ann Pharmacother. 1998;32:580–6.CrossRef DeCamara J, Dowless H. Glucosamine sulfate role in osteoarthritis. Ann Pharmacother. 1998;32:580–6.CrossRef
3.
go back to reference Leeb B, Wiedmeyer HM, Bartol T. Meta-analysis of Chondroitin Sulfate in treatment of Osteoarthritis. J Rheumatol. 2000;27:205–11.PubMed Leeb B, Wiedmeyer HM, Bartol T. Meta-analysis of Chondroitin Sulfate in treatment of Osteoarthritis. J Rheumatol. 2000;27:205–11.PubMed
4.
go back to reference Katzung BG. Basic and clinical pharmacology. 10th ed. New York: McCrew; 2007. p. 356–69. Katzung BG. Basic and clinical pharmacology. 10th ed. New York: McCrew; 2007. p. 356–69.
5.
go back to reference Bunn HF, Bunn HF, Haney DN, Gabbay KH. Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem Biophys Res Commun. 1975;67(1):103–9.PubMedCrossRef Bunn HF, Bunn HF, Haney DN, Gabbay KH. Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem Biophys Res Commun. 1975;67(1):103–9.PubMedCrossRef
6.
go back to reference Michigan Diabetes Research & Training Center. Developing Point of care HbA1c tests for Diabetes monitoring, 2000; Dec: 26. Michigan Diabetes Research & Training Center. Developing Point of care HbA1c tests for Diabetes monitoring, 2000; Dec: 26.
7.
go back to reference Larsen ML, Hørder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in non insulin-dependent diabetes mellitus. N Engl J Med. 1990;323(15):1022–3.CrossRef Larsen ML, Hørder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in non insulin-dependent diabetes mellitus. N Engl J Med. 1990;323(15):1022–3.CrossRef
8.
go back to reference Rohlfing C, Wiedmeyer HM, Little R. Biological variation of glycohemoglobin. Clin Chem. 2002;48(7):1116–8.PubMed Rohlfing C, Wiedmeyer HM, Little R. Biological variation of glycohemoglobin. Clin Chem. 2002;48(7):1116–8.PubMed
9.
go back to reference Lehman R, Krumholz HM. Tight control of blood glucose in long standing type 2 diabetes. Br Med J. 2009;338:b800.CrossRef Lehman R, Krumholz HM. Tight control of blood glucose in long standing type 2 diabetes. Br Med J. 2009;338:b800.CrossRef
10.
go back to reference Nathan DM, Singer DE, Hurxthal K. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310:341–6.PubMedCrossRef Nathan DM, Singer DE, Hurxthal K. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310:341–6.PubMedCrossRef
11.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care. 2007;30 Suppl 1:S4–S41.CrossRef American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care. 2007;30 Suppl 1:S4–S41.CrossRef
Metadata
Title
Is glucosamine-chondroitin risky to normoglycemic individuals with family history of diabetes mellitus
Authors
Rafi A. M. Al-Razzuqi
Ali A. Al-Jeboori
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
International Journal of Diabetes in Developing Countries / Issue 1/2011
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-010-0012-0

Other articles of this Issue 1/2011

International Journal of Diabetes in Developing Countries 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine